Complement Inactivator Proteins

All categories
DBCAT002770Pharmacologic class

Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. A DrugBank category of 5 drugs. 5 of them are approved.

Also known as
Complement Cytolysis Inhibiting Proteins · Complement Cytolysis Inhibitor Proteins · Complement Inactivating Proteins · Complement Inactivators, Serum · Inactivating Proteins, Complement
Drugs

What you can answer from here — as of October 03, 2016

5DrugsEach linked to its full drug card
Listed above
10Drug targetsEvery drug–target pair in the class, with bond type
Sign in
59Marketed productsAcross the regions we cover, with dosage forms and routes
Sign in
4Routes of administrationHow the drugs in this class are given
Sign in

Which targets do Complement Inactivator Proteins share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In